Wall Street Journal, Feb. 28, 2011
That’s a big expansion from previous guidelines, which suggested flu shots for healthy kids only through age 5, and could mean 30 million more kids will be in line to be vaccinated.
An expansion could give a boost to AstraZeneca, which last year paid some $16 billion to acquire MedImmune, which makes a nasal flu vaccine that’s approved for children age two and over. (No more excuses about painful shots, kiddos.) The company said yesterday that it plans to make 12 million doses of the vaccine this year, the most ever.